

Yarvitan (WD) 5 mg/ml - Oral solution

Not
authorised

- Mitratapide

Product identification

Medicine name:

Yarvitan (WD) 5 mg/ml - Oral solution

Active substance:

Mitratapide

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Mitratapide

5.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Oral solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QA08AB90

Legal status of supply:

Medicinal product subject to medical prescription

Authorisation status:

Surrendered

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Janssen Pharmaceutica

Marketing authorisation date:

14/11/2006

Manufacturing sites for batch release:

Janssen Pharmaceutica

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

14/11/2006

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet